Key Highlights
- 1.0% is the premium of USD 73.24 for Oruka Therapeutics (NASDAQ:ORKA) on October 16, 2026 over the USD 72.50 price of its April 28 offering (own arithmetic). The 14-day RSI is 29.6, the one-week change is negative 5.18%, and market capitalization is USD 4.85 billion.
- USD 700.4 million was gross proceeds from the upsized April 2026 offering of 9.66 million shares, per the company release. Cash and marketable securities were USD 1.1 billion at June 30, 2026, or 22.7% of current market capitalization (own arithmetic).
- 71.4% of patients reached PASI 100, clear skin, at Week 28 in the EVERLAST-A trial of ORKA-001, up from 63.5% at Week 16, per the September 23 data. Oruka Therapeutics (NASDAQ:ORKA) shares fell 5% that morning.
- Q4 2026 is when Week 16 data from the 187-subject EVERLAST-B Phase 2b trial are due, with 52-week EVERLAST-A data in December 2026. Third quarter results are estimated for November 11, 2026; no date was found in company filings.
Price Action and Catalyst Review
The tension is that strong data and a strong balance sheet have not held the price. The 52-week range is USD 25.11 to USD 115.52, so the stock is 36.6% below its high and 2.9 times its low (own arithmetic). The Week 28 results on September 23 showed PASI 90 of 87.3%, and an analyst at Clear Street said the update met its base case, so the data confirmed rather than beat expectations. No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026.
Mechanism, Cash and Burn
ORKA-001 is a half-life extended antibody against IL-23p19, the signal that drives psoriatic inflammation. Longer half-life is the commercial thesis: the company says 52-week data will inform once- to twice-yearly dosing. Responses kept increasing six months after the final dose, with no treatment after Week 4. Second quarter net loss was USD 41.2 million and research expense USD 43.3 million, including a non-refundable upfront payment to Halozyme. At the first-half net loss of USD 73.0 million annualized to USD 146 million, USD 1.1 billion funds 7.5 years (own arithmetic), before Phase 3 costs.
Valuation, Support and Risks
Oruka has no product revenue, so valuation rests on approval odds. Consensus is Strong Buy from 13 analysts with an average target of USD 155.00, 111.6% above USD 73.24 (own arithmetic). The April offering price of USD 72.50 is a reference level, not a guaranteed floor. Risks are specific: a Phase 2a trial of 84 patients is small, the Phase 3 program is not expected to begin until the first half of 2027, and an adverse EVERLAST-B readout would reprice the stock. RSI is not a forecast.
Where Things Stand
Oruka Therapeutics (NASDAQ:ORKA) is oversold because it fell 5.18% in a week and now trades 36.6% below its high, with no new company disclosure to explain the latest move; the best-supported explanation is positioning ahead of the Q4 EVERLAST-B readout and a reset after strong data was largely expected, labelled as inference. The balance sheet of USD 1.1 billion is large against a USD 4.85 billion market capitalization, and the April offering price is a reference level. The next dated catalysts are EVERLAST-B Week 16 data in the fourth quarter, 52-week EVERLAST-A data in December, and estimated results on November 11, 2026.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...